Biotechnology
Singleron Biotechnologies and Macrogen Europe announce a strategic alliance
Singleron Biotechnologies and Macrogen Europe are happy to announce their
collaboration to combine their strengths to provide first-class single cell
multi-omics sequencing solutions.
COLOGNE, Germany, Feb. 27, 2023 /PRNewswire/ -- Singleron Biotechnologies
2023-02-27 16:00
1550
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS * Total Group revenue $160.1M ...
2023-02-27 14:37
1749
Porton Advanced and Yinjia Biosciences Partner to Enhance CDMO Technology Platform
SUZHOU, China, Feb. 24, 2023 /PRNewswire/ -- On February 20, 2023, Porton Advanced Solutions Ltd. (Porton Advanced) and Yinjia (Shanghai) Biosciences Co., Ltd. (Yinjia Biosciences) announced a strategic partnership in developing core protein raw materials for cell and gene therapy (CGT) and test ...
2023-02-24 20:00
1642
Dr. Lilly Xu Named President of Shanghai ChemPartner
SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- ChemPartner
2023-02-24 05:53
1978
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China
SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Today, Invivoscribe announced that its Shanghai lab in China has received CAP accreditation. The College of American Pathologists (CAP) is a professional organization that accredits clinical laboratories across the world. The CAP accreditation process is ...
2023-02-23 22:00
2461
Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymp...
2023-02-23 15:02
1622
World-renowned therapist and wellness expert Marisa Peer endorses natural prebiotic Kfibre & Kfibre Pro Synbiotics for advanced gut health management.
Heal the Gut, Heal the Mind SYDNEY, Feb. 23, 2023 /PRNewswire/ -- As a pioneering therapist, speaker, best-selling author, and the founder of Rapid Transformational Therapy (RTT®), Marisa's guiding ethos is centred on simple steps that produce dramatic and life-saving results. One of those step...
2023-02-23 13:31
1781
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901
CHENGDU, China, Feb. 23, 2023 /PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class C...
2023-02-23 13:01
1665
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudi...
2023-02-23 12:26
2279
Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration
* Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out discussions. * Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025. DAEJEON, So...
2023-02-22 22:00
1916
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
TOKYO, Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity...
2023-02-22 21:05
2289
GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate
PISCATAWAY, N.J. and SINGAPORE, Feb. 22, 2023 /PRNewswire/ -- GenScript ProBio, a leading global Contract Development and Manufacturing Organization (CDMO), and RVAC Medicines Pte. Ltd., a biotechnology company focusing on the development and commercialization of messenger RNA (mRNA) therapeu...
2023-02-22 21:00
2233
AnPac Bio Announces Positive Results from its Multi-Year and Multi-Cancer Test Follow-Up Study
NEW YORK, Feb. 22, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commer...
2023-02-22 20:30
2016
Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA
SHENZHEN, China, Feb. 22, 2023 /PRNewswire/ -- Fapon Biopharma, an innovative biotech company, announced today that its Investigational New Drug (IND) application of FP002, an anti-CD47 monoclonal antibody drug candidate, has been approved by FDA for clinical trials. FP002 is a humanized anti-CD...
2023-02-22 20:17
1729
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, an...
2023-02-21 23:04
2705
Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON
WUHAN, China and SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in the Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON) inChina. It marks the completion of patient enr...
2023-02-21 21:30
2392
NMPA accepted the registration applications for Uro-G and Uro-3500
SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the registration applications for ...
2023-02-21 17:46
1780
Synbio Tech Inc. and Cosmax Group signed an exclusive cooperation agreement to jointly expand the South Korean probiotics market
KAOHSIUNG, Taiwan, Feb. 21, 2023 /PRNewswire/ -- Synbio Tech Inc. and Cosmax NBT, a major South Korean biotechnology company officially signed an exclusive cooperation agreement to launchLactobacillus plantarum TWK10® probiotic strain inSouth Korea, and announced that TWK10® has been approved as ...
2023-02-21 16:01
2318
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces t...
2023-02-21 14:00
2971
RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore
SINGAPORE, Feb. 20, 2023 /PRNewswire/ -- RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immuno...
2023-02-21 10:00
1766
Week's Top Stories
Most Reposted
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
[Picked up by 331 media titles]
2024-05-23 10:00
SINGAPORE'S XSQUARE TECHNOLOGIES SECURES S$10.5M IN SERIES A FUNDING LED BY WAVEMAKER PARTNERS
[Picked up by 326 media titles]
2024-05-23 10:00Unlock the Future of Innovation: Taiwan's Premier Hardware Expo Hits the Global Stage This October
[Picked up by 314 media titles]
2024-05-24 09:41
Ultima Markets partnered with Willis Towers Watson (WTW) to offer US$1 million in fund insurance
[Picked up by 303 media titles]
2024-05-24 12:00
Getac Announces World's First AI-Ready Rugged Laptop
[Picked up by 300 media titles]
2024-05-29 08:00
Most Read
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
2024-05-23 10:00
12172
Revolutionising Cardiac Care at Pantai Hospital Kuala Lumpur
2024-05-23 11:22
10640
